Double-blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis
Latest Information Update: 17 Feb 2022
At a glance
- Drugs Desloratadine (Primary)
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Acronyms ACCEPT-2
- Sponsors Schering-Plough
- 13 Jun 2019 Trial has been completed in Greece.
- 17 Mar 2009 Results reported at AAAAI 2009.
- 06 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.